倍他乐克联合辅酶Q10治疗扩张型心肌病临床研究.doc

倍他乐克联合辅酶Q10治疗扩张型心肌病临床研究[摘要] 目的 观察倍他乐克联合辅酶Q10治疗扩张型心肌病的临床疗效及安全性。方法 对66例扩张型心肌病患者随机分为两组,在限制体力活动低盐饮食、应用洋地黄利尿剂及ACEI制剂的基础上,实验组加用倍他乐克和辅酶Q10治疗。组间分别进行疗效观察。结果 治疗3个月后实验组QT离散度、LVEF、SBP、DBP、HR及心功能分级与对照组比较均有显著性差异,未见特殊严重不良反应。结论 倍他乐克联合辅酶Q10治疗扩张型心肌病可显著改善患者心功能和预后,降低猝死率,临床疗效可靠、安全。 [关键词] 倍他乐克; 辅酶Q10; 扩张型心肌病; QT离散度; 心功能; 猝死 [中图分类号] R542.2 [文献标识码] A [文章编号] 1673-9701(2010)03-115-02 Betaloc Combined with Coenzyme Q10 in the Treatment of Dilated Cardiomyopathy:A Clinical Analysis DONG Zebo LI Guangxia Department of Internal Medicine,Mingshan County People’s Hospital,Mingshan 625100,China [Abstract] ObjectiveTo observe the clinical efficacy and safety ofbetaloc combined with coenzyme Q10 for dilated cardiomyopathy. MethodsWe divided 66 cases of dilated cardiomyopathy randomly into two groups. Both groups were given limit physical activity,a low-salt diet,a small dose of digitalis diuretics and ACEI preparation,and betaloc and coenzyme Q10 were added to the treatment group. Comparison was made of curative effect between the two groups separately. Results3 months after treatment,the QT dispersion,LVEF,SBP,DBP,HR and cardiac functional class in the treatment group were significantly different compared with the control group,with no specific serious adverse reactions. ConclusionCombination of betaloc and coenzyme Q10 in the treatment of dilated cardiomyopathy can significantly improve cardiac function and prognosis and reduce the sudden death rate,with reliable clinical efficacy and safety. [Key words]Betaloc; Coenzyme Q10; Dilated cardiomyopathy; QT dispersion; Heart function; Sudden death 扩张型心肌病是一种病因未明、起病隐袭、发病年龄相对偏低、以全心扩大为主要病理表现的心脏疾病,常伴有充血性心力衰竭和心律失常,病情进展较快,临床上猝死率高。目前尚无特殊治疗方法。我院内科探讨在限制体力活动、低盐饮食、应用洋地黄、利尿剂及ACEI制剂的基础上加用倍他乐克和辅酶Q10口服治疗扩张型心肌病的疗效,观察不良反应,现报道如下。 1 资料与方法 1.1 研究对象 纳入我院2005年1月～2009年9月门诊和住院的扩张型心肌病患者共66例,按NYHM分级心功能Ⅱ～Ⅳ级,随机分为两组。其中实验组33例,男21例,女12例,平均年龄(51±7.1)岁,病程3个月～6年,平均2.5年。对照组33例,男21例,女12例,平均年龄52±8.3岁,病程6个月～5年,平均2.2年。观察中实验组猝死1例,对照组因心力衰竭死亡1例。所有患者均符合窦性心律,无高血压、冠